These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 36316882)
1. Evaluation of nephrotoxicity and ototoxicity following amikacin administration once daily or every 48 hours in neonates. Endo A; Hanawa K; Nemoto A; Ishikawa T; Kazama S; Kagami Y; Maebayashi Y; Katsumata N; Naito A; Kobayashi Y; Kawano Y; Hanawa T Medicine (Baltimore); 2022 Oct; 101(43):e31425. PubMed ID: 36316882 [TBL] [Abstract][Full Text] [Related]
2. Relationship between amikacin blood concentration and ototoxicity in low birth weight infants. Endo A; Nemoto A; Hanawa K; Maebayashi Y; Hasebe Y; Kobayashi M; Naito A; Kobayashi Y; Yamamoto S; Isobe K J Infect Chemother; 2019 Jan; 25(1):17-21. PubMed ID: 30539740 [TBL] [Abstract][Full Text] [Related]
3. [In the search for effective and safe dose of amikacin in patients with chronic kidney disease]. Gomółka M; Szamotulska K; Rymarz A; Brodowska-Kania D; Dubchak I; Piechota W; Jurkiewicz D; Niemczyk S Pol Merkur Lekarski; 2014 Apr; 36(214):240-4. PubMed ID: 24868895 [TBL] [Abstract][Full Text] [Related]
4. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719 [TBL] [Abstract][Full Text] [Related]
6. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Langhendries JP; Battisti O; Bertrand JM; François A; Darimont J; Ibrahim S; Tulkens PM; Bernard A; Buchet JP; Scalais E Dev Pharmacol Ther; 1993; 20(3-4):220-30. PubMed ID: 7828457 [TBL] [Abstract][Full Text] [Related]
7. Protective effect of pentoxifylline on amikacin-induced ototoxicity. El-Anwar MW; Abdelmonem S; Nada E; Galhoom D; Abdelsameea AA Ear Nose Throat J; 2018 Aug; 97(8):E8-E12. PubMed ID: 30138519 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of amikacin in septic patients. Duszynska W; Taccone FS; Hurkacz M; Kowalska-Krochmal B; Wiela-Hojeńska A; Kübler A Crit Care; 2013 Jul; 17(4):R165. PubMed ID: 23886243 [TBL] [Abstract][Full Text] [Related]
9. Once-daily dosing of amikacin for treatment of Lee H; Sohn YM; Ko JY; Lee SY; Jhun BW; Park HY; Jeon K; Kim DH; Kim SY; Choi JE; Moon IJ; Shin SJ; Park HJ; Koh WJ Int J Tuberc Lung Dis; 2017 Jul; 21(7):818-824. PubMed ID: 28633708 [TBL] [Abstract][Full Text] [Related]
10. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. Marik PE; Lipman J; Kobilski S; Scribante J J Antimicrob Chemother; 1991 Nov; 28(5):753-64. PubMed ID: 1778878 [TBL] [Abstract][Full Text] [Related]
11. Influence of Spirulina platensis and ascorbic acid on amikacin-induced nephrotoxicity in rabbits. Abdel-Daim MM; Ahmed A; Ijaz H; Abushouk AI; Ahmed H; Negida A; Aleya L; Bungau SG Environ Sci Pollut Res Int; 2019 Mar; 26(8):8080-8086. PubMed ID: 30685861 [TBL] [Abstract][Full Text] [Related]
12. Protective effect of ethyl pyruvate on amikacin-induced ototoxicity in rats. Dedeoğlu S; Ayral M Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2460-2466. PubMed ID: 35442461 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of amikacin in preterm and term infants. Siddiqi A; Khan DA; Khan FA; Razzaq A Singapore Med J; 2009 May; 50(5):486-9. PubMed ID: 19495517 [TBL] [Abstract][Full Text] [Related]
15. [Protective effect by piperacillin against renal impairment caused by amikacin]. Kusafuka H; Obayashi T; Iwayama N; Sezaki R; Izuhara Y; Yoshida H; Goto M; Maeda K Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):153-62. PubMed ID: 1588766 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic variability of amikacin after once-daily and twice-daily dosing regimen in full-term neonates. Vučićević K; Rakonjac Z; Miljković B; Janković B; Prostran M J Pharmacol Sci; 2014; 124(2):138-43. PubMed ID: 24441865 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. Sánchez-Alcaraz A; Vargas A; Quintana MB; Rocher A; Querol JM; Poveda JL; Hermenegildo M J Clin Pharm Ther; 1998 Oct; 23(5):367-73. PubMed ID: 9875685 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series. Namkoong H; Morimoto K; Nishimura T; Tanaka H; Sugiura H; Yamada Y; Kurosaki A; Asakura T; Suzuki S; Fujiwara H; Yagi K; Ishii M; Tasaka S; Betsuyaku T; Hoshino Y; Kurashima A; Hasegawa N BMC Infect Dis; 2016 Aug; 16():396. PubMed ID: 27506679 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the renal and auditory function of neonates treated with amikacin. Parini R; Rusconi F; Cavanna G; Vigliani E; Cornacchia L; Assael BM Dev Pharmacol Ther; 1982; 5(1-2):33-46. PubMed ID: 7151635 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms and pharmacokinetic/pharmacodynamic profiles underlying the low nephrotoxicity and ototoxicity of etimicin. Yao L; Zhang JW; Chen B; Cai MM; Feng D; Wang QZ; Wang XY; Sun JG; Zheng YW; Wang GJ; Zhou F Acta Pharmacol Sin; 2020 Jun; 41(6):866-878. PubMed ID: 31937930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]